Standard of care for patients with HER2+ breast cancer is the antibody drug conjugate ado-trastuzumab (T-DM1), which has improved the median OS of patients with progressive disease by 4 and 7 months in the EMILIA and TH3RESA trial, respectively8,9. This evidence concerns the gene ERBB2 and breast carcinoma.